These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27471827)

  • 1. RANIBIZUMAB FOR MACULAR EDEMA AFTER BRANCH RETINAL VEIN OCCLUSION: One Initial Injection Versus Three Monthly Injections.
    Miwa Y; Muraoka Y; Osaka R; Ooto S; Murakami T; Suzuma K; Takahashi A; Iida Y; Yoshimura N; Tsujikawa A
    Retina; 2017 Apr; 37(4):702-709. PubMed ID: 27471827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema following Central Retinal Vein Occlusion: 1 Initial Injection versus 3 Monthly Injections.
    Osaka R; Muraoka Y; Miwa Y; Manabe K; Kobayashi M; Takasago Y; Ooto S; Murakami T; Suzuma K; Iida Y; Tsujikawa A
    Ophthalmologica; 2018; 239(1):27-35. PubMed ID: 28946138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials.
    Thach AB; Yau L; Hoang C; Tuomi L
    Ophthalmology; 2014 May; 121(5):1059-66. PubMed ID: 24424249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SHORT-TERM EFFECT OF INTRAVITREAL RANIBIZUMAB THERAPY ON MACULAR EDEMA AFTER BRANCH RETINAL VEIN OCCLUSION.
    Minami Y; Nagaoka T; Ishibazawa A; Yoshida A
    Retina; 2016 Sep; 36(9):1726-32. PubMed ID: 26866527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study.
    Campochiaro PA; Wykoff CC; Singer M; Johnson R; Marcus D; Yau L; Sternberg G
    Ophthalmology; 2014 Dec; 121(12):2432-42. PubMed ID: 25060610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study.
    Tadayoni R; Waldstein SM; Boscia F; Gerding H; Gekkieva M; Barnes E; Das Gupta A; Wenzel A; Pearce I;
    Ophthalmology; 2017 Dec; 124(12):1778-1787. PubMed ID: 28807635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twenty-Four Month Results of Intravitreal Ranibizumab for Macular Edema after Branch Retinal Vein Occlusion: Visual Outcomes and Resolution of Macular Edema.
    Inagaki M; Hirano Y; Yasuda Y; Kawamura M; Suzuki N; Yasukawa T; Yoshida M; Ogura Y
    Semin Ophthalmol; 2021 Oct; 36(7):482-489. PubMed ID: 33617388
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion.
    Risard SM; Pieramici DJ; Rabena MD; Basefsky JC; Avery RL; Castellarin AA; Nasir MA; See RF; Couvillion SS
    Retina; 2011 Jun; 31(6):1060-7. PubMed ID: 21283055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal conbercept for branch retinal vein occlusion induced macular edema: one initial injection versus three monthly injections.
    Chen X; Hu TM; Zuo J; Wu H; Liu ZH; Zhan YX; Xia Y; Wang J; Wei W
    BMC Ophthalmol; 2020 Jun; 20(1):225. PubMed ID: 32527234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B).
    Hattenbach LO; Feltgen N; Bertelmann T; Schmitz-Valckenberg S; Berk H; Eter N; Lang GE; Rehak M; Taylor SR; Wolf A; Weiss C; Paulus EM; Pielen A; Hoerauf H;
    Acta Ophthalmol; 2018 Feb; 96(1):e10-e18. PubMed ID: 28251811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing ranibizumab, dexamethasone implant, and combined therapy for macular edema secondary to branch retinal vein occlusion: a clinical trial.
    Meng L; Yang M; Jiang X; Li Y; Han X
    Int Ophthalmol; 2024 Jun; 44(1):262. PubMed ID: 38913192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion: 12-month results.
    Nishimura T; Machida S; Tada A; Oshida E; Muto T
    Doc Ophthalmol; 2020 Oct; 141(2):127-136. PubMed ID: 32100140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macular vessel reduction as predictor for recurrence of macular oedema requiring repeat intravitreal ranibizumab injection in eyes with branch retinal vein occlusion.
    Hasegawa T; Takahashi Y; Maruko I; Kogure A; Iida T
    Br J Ophthalmol; 2019 Oct; 103(10):1367-1372. PubMed ID: 30514711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a Treat-and-Eextend Regimen of Intravitreal Ranibizumab Injection for Macular Edema due to Branch Retinal Vein Occlusion.
    Hosogi M; Morizane Y; Shiode Y; Doi S; Kumase F; Kimura S; Hosokawa M; Hirano M; Toshima S; Takahashi K; Fujiwara A; Shiraga F
    Acta Med Okayama; 2018 Feb; 72(1):39-45. PubMed ID: 29463937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER.
    Tadayoni R; Waldstein SM; Boscia F; Gerding H; Pearce I; Priglinger S; Wenzel A; Barnes E; Gekkieva M; Pilz S; Monés J;
    Ophthalmology; 2016 Jun; 123(6):1332-44. PubMed ID: 27039022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of clinical efficacy of intravitreal ranibizumab with and without triamcinolone acetonide in macular edema secondary to central retinal vein occlusion.
    Fan C; Wang Y; Ji Q; Zhao B; Xie J
    Curr Eye Res; 2014 Sep; 39(9):938-43. PubMed ID: 24635755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectral-Domain Optical Coherence Tomography-Driven Treat-and-Extend and Pro Re Nata Regimen in Patients with Macular Oedema due to Retinal Vein Occlusion: 24-Month Evaluation and Outcome Predictors.
    Guichard MM; Xavier AR; Türksever C; Pruente C; Hatz K
    Ophthalmic Res; 2018; 60(1):29-37. PubMed ID: 29566387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Conbercept with Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion.
    Li F; Sun M; Guo J; Ma A; Zhao B
    Curr Eye Res; 2017 Aug; 42(8):1174-1178. PubMed ID: 28441077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
    Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
    Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):267-279. PubMed ID: 29185099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal PRN ranibizumab treatment for macular edemadue to branch retinal vein occlusion.
    Çakmak HB; Arikan Yorgun M; Toklu Y; Mutlu M
    Turk J Med Sci; 2017 Feb; 47(1):40-46. PubMed ID: 28263518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.